Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis

Eliaz Therapeutics announced that its XGal-3 apheresis device has received FDA Breakthrough Device Designation for treating sepsis, a leading cause of death in ICUs. The company is launching a Regulation Crowdfunding round to support GLP safety studies and first-in-human clinical trials. With $8M raised to date from over 1,700 investors and support from NIH grants and Terumo BCT collaboration, XGal-3 aims to selectively remove Galectin-3 protein to address inflammatory dysregulation in sepsis.

06/11/2026, 5:51 PM • GlobeNewswire

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Orchestra BioMed presented clinical data showing AVIM therapy can sustainably reduce blood pressure in patients, with effects that are reversible and reproducible upon reactivation after a washout period.

09/04/2025, 5:00 PM • GlobeNewswire

Patient Blood Management Market Growth Analysis Report 2025-2033 | AI-Driven Analytics Revolutionize Blood Management Strategies, Blockchain Enhances Supply Transparency and Safety

The Patient Blood Management market is projected to grow from $13.9 billion in 2025 to $23 billion by 2033, driven by AI-enhanced analytics, autologous transfusion technologies, and advancements in blood conservation techniques.

08/14/2025, 10:58 AM • GlobeNewswire

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Orchestra BioMed received FDA approval to expand patient eligibility for its BACKBEAT study, potentially increasing the eligible patient pool by over 24-fold and supporting its mid-2026 enrollment target for AVIM therapy in treating uncontrolled hypertension.

08/08/2025, 7:00 AM • GlobeNewswire